[CIMB] QoQ Quarter Result on 30-Jun-2019 [#2]

Stock
[CIMB] CIMB GROUP HOLDINGS BERHAD
Announcement Date
29-Aug-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2019
Quarter
30-Jun-2019 [#2]
Profit Trend
QoQ- 26.56%
YoY- -23.84%
Quarter Report
Latest QR
Upcoming QR
CIMB's Result
CIMB's Financial Summary
View:
Show?
Quarter Result
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Revenue 4,143,029 4,522,437 4,638,445 4,468,851 4,166,146 4,074,543 4,140,536 0.04%
PBT 713,964 1,079,002 1,336,883 1,955,829 1,603,126 1,512,213 1,486,401 -38.63%
Tax -215,208 -312,903 -350,550 -460,760 -395,440 -394,440 -294,840 -18.91%
NP 498,756 766,099 986,333 1,495,069 1,207,686 1,117,773 1,191,561 -44.01%
-
NP to SH 507,925 848,641 1,010,348 1,508,625 1,192,042 1,117,135 1,179,718 -42.95%
-
Tax Rate 30.14% 29.00% 26.22% 23.56% 24.67% 26.08% 19.84% -
Total Cost 3,644,273 3,756,338 3,652,112 2,973,782 2,958,460 2,956,770 2,948,975 15.14%
-
Net Worth 54,696,383 55,791,709 56,078,569 54,592,153 52,835,961 51,096,139 50,010,532 6.14%
Dividend
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Div - 1,181,318 - 1,355,821 - 1,141,515 - -
Div Payout % - 139.20% - 89.87% - 102.18% - -
Equity
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Net Worth 54,696,383 55,791,709 56,078,569 54,592,153 52,835,961 51,096,139 50,010,532 6.14%
NOSH 9,922,971 9,922,971 9,727,423 9,727,423 9,564,459 9,564,459 9,365,799 3.92%
Ratio Analysis
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
NP Margin 12.04% 16.94% 21.26% 33.46% 28.99% 27.43% 28.78% -
ROE 0.93% 1.52% 1.80% 2.76% 2.26% 2.19% 2.36% -
Per Share
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
RPS 41.75 45.94 47.68 46.14 43.56 42.83 44.21 -3.74%
EPS 5.12 8.56 10.36 15.60 12.46 11.67 12.56 -44.99%
DPS 0.00 12.00 0.00 14.00 0.00 12.00 0.00 -
NAPS 5.5121 5.6674 5.765 5.6371 5.5242 5.3714 5.3397 2.13%
Adjusted Per Share Value based on latest NOSH - 9,727,423
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
RPS 38.65 42.19 43.27 41.69 38.86 38.01 38.63 0.03%
EPS 4.74 7.92 9.43 14.07 11.12 10.42 11.01 -42.95%
DPS 0.00 11.02 0.00 12.65 0.00 10.65 0.00 -
NAPS 5.1025 5.2046 5.2314 5.0927 4.9289 4.7666 4.6653 6.14%
Price Multiplier on Financial Quarter End Date
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Date 31/03/20 31/12/19 30/09/19 28/06/19 29/03/19 31/12/18 28/09/18 -
Price 3.60 5.15 5.03 5.38 5.15 5.71 6.01 -
P/RPS 8.62 11.21 10.55 11.66 11.82 13.33 13.59 -26.15%
P/EPS 70.33 59.74 48.43 34.54 41.32 48.62 47.71 29.49%
EY 1.42 1.67 2.06 2.90 2.42 2.06 2.10 -22.94%
DY 0.00 2.33 0.00 2.60 0.00 2.10 0.00 -
P/NAPS 0.65 0.91 0.87 0.95 0.93 1.06 1.13 -30.81%
Price Multiplier on Announcement Date
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Date 22/05/20 28/02/20 22/11/19 29/08/19 29/05/19 28/02/19 29/11/18 -
Price 3.47 4.82 5.37 4.94 5.15 5.85 5.85 -
P/RPS 8.31 10.49 11.26 10.71 11.82 13.66 13.23 -26.63%
P/EPS 67.79 55.91 51.70 31.71 41.32 49.81 46.44 28.65%
EY 1.48 1.79 1.93 3.15 2.42 2.01 2.15 -22.02%
DY 0.00 2.49 0.00 2.83 0.00 2.05 0.00 -
P/NAPS 0.63 0.85 0.93 0.88 0.93 1.09 1.10 -31.01%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment